SE0202157D0 - Methods for identification of compounds modulating insulin resistance - Google Patents

Methods for identification of compounds modulating insulin resistance

Info

Publication number
SE0202157D0
SE0202157D0 SE0202157A SE0202157A SE0202157D0 SE 0202157 D0 SE0202157 D0 SE 0202157D0 SE 0202157 A SE0202157 A SE 0202157A SE 0202157 A SE0202157 A SE 0202157A SE 0202157 D0 SE0202157 D0 SE 0202157D0
Authority
SE
Sweden
Prior art keywords
methods
insulin resistance
identification
compounds modulating
modulating insulin
Prior art date
Application number
SE0202157A
Other languages
English (en)
Inventor
Stephen James
Christina Kaiser
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Priority to SE0202157A priority Critical patent/SE0202157D0/sv
Publication of SE0202157D0 publication Critical patent/SE0202157D0/sv
Priority to CA002487856A priority patent/CA2487856A1/en
Priority to EP03762946A priority patent/EP1539217A2/en
Priority to AU2003243107A priority patent/AU2003243107A1/en
Priority to PCT/SE2003/001126 priority patent/WO2004005881A2/en
Priority to JP2004519445A priority patent/JP2005535316A/ja
Priority to US10/615,252 priority patent/US20040058868A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE0202157A 2002-07-09 2002-07-09 Methods for identification of compounds modulating insulin resistance SE0202157D0 (sv)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE0202157A SE0202157D0 (sv) 2002-07-09 2002-07-09 Methods for identification of compounds modulating insulin resistance
CA002487856A CA2487856A1 (en) 2002-07-09 2003-06-27 Methods for identification of compounds modulating insulin resistance
EP03762946A EP1539217A2 (en) 2002-07-09 2003-06-27 Methods for identification of compounds modulating insulin resistance
AU2003243107A AU2003243107A1 (en) 2002-07-09 2003-06-27 Methods for identification of compounds modulating insulin resistance
PCT/SE2003/001126 WO2004005881A2 (en) 2002-07-09 2003-06-27 Methods for identification of compounds modulating insulin resistance
JP2004519445A JP2005535316A (ja) 2002-07-09 2003-06-27 インスリン耐性をモジュレーションする化合物の同定方法
US10/615,252 US20040058868A1 (en) 2002-07-09 2003-07-08 Methods for identification of compounds modulating insulin resistance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202157A SE0202157D0 (sv) 2002-07-09 2002-07-09 Methods for identification of compounds modulating insulin resistance

Publications (1)

Publication Number Publication Date
SE0202157D0 true SE0202157D0 (sv) 2002-07-09

Family

ID=20288493

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0202157A SE0202157D0 (sv) 2002-07-09 2002-07-09 Methods for identification of compounds modulating insulin resistance

Country Status (7)

Country Link
US (1) US20040058868A1 (sv)
EP (1) EP1539217A2 (sv)
JP (1) JP2005535316A (sv)
AU (1) AU2003243107A1 (sv)
CA (1) CA2487856A1 (sv)
SE (1) SE0202157D0 (sv)
WO (1) WO2004005881A2 (sv)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014626A2 (en) 2003-02-28 2005-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant human metapneumovirus and its use
EP1608628A2 (en) * 2003-03-17 2005-12-28 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
US20060073213A1 (en) * 2004-09-15 2006-04-06 Hotamisligil Gokhan S Reducing ER stress in the treatment of obesity and diabetes
JP2008513465A (ja) * 2004-09-15 2008-05-01 ザ プレジデント アンド フェロウズ オブ ハーバード カレッジ 肥満及び糖尿病の治療におけるｅｒストレス低減
US7642275B2 (en) * 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008530136A (ja) 2005-02-14 2008-08-07 ミイカナ セラピューティクス インコーポレイテッド ヒストンデアセチラーゼの阻害剤として有用な縮合複素環化合物
EP1896436A2 (en) * 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2006270322A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US20110077300A1 (en) * 2009-03-26 2011-03-31 Jianping Ye Metabolic Benefits to Butyrate as a Chronic Diet Supplement

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110970A (en) * 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Nitrogen-containing oxyalkylene esters and uses thereof
US6020374A (en) * 1998-05-14 2000-02-01 Ramot University Authority For Applied Research & Industrial Development Ltd. Biologically active synthetic dye compounds
AUPP505798A0 (en) * 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance
AU2001277105A1 (en) * 2000-07-21 2002-02-05 Millennium Pharmaceuticals, Inc. 47508, a novel human histone deacetylase family member and uses thereof

Also Published As

Publication number Publication date
JP2005535316A (ja) 2005-11-24
US20040058868A1 (en) 2004-03-25
WO2004005881A3 (en) 2004-04-01
CA2487856A1 (en) 2004-01-15
AU2003243107A1 (en) 2004-01-23
EP1539217A2 (en) 2005-06-15
WO2004005881A2 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
SE0202157D0 (sv) Methods for identification of compounds modulating insulin resistance
DE60330541D1 (de) System zum Verfolgen von Poststücken
BRPI0600777A (pt) método e sistema para a criação, armazenamento, gerenciamento e consumo de dados especìficos de cultura
BR9710570A (pt) Inibidor de adesão de células
NO20091734L (no) Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse
NO20052887D0 (no) Pyridazinonderivater som GSK-3Beta inhibitorer.
ATE361922T1 (de) Pyrrol-substituierte indole als inhibitoren von pai-1
DE69737592D1 (de) Mittel gegen juckreiz
CY1109414T1 (el) Ν-σουλφονυλ πυρρολια και χρηση αυτων ως αναστολεις αποακετυλασης ιστονης
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
WO2004005513A3 (en) Methods for specifically inhibiting histone deacetylase-7 and 8
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
BRPI0515079A (pt) marcadores imobilizados e métodos de detecção de prions conformacionalmente alterados
PT1454992E (pt) Ensaio de quinase do linfoma anaplastico, reagentes e composicoes
MXPA05008904A (es) Metodo para estimar el efecto antitumoral del inhibidor de desacetilasa de histona.
WO2010031988A3 (en) Polypeptides substrates of lrrk2 and uses thereof
TW200621744A (en) Mercaptoamides as histone deacetylase inhibitors
ATE487141T1 (de) Hemmung von gasc1
FR2929758B1 (fr) Procede de transfert a l'aide d'un substrat ferroelectrique
WO2006055959A3 (en) Pf4 pharmacophores and their uses
ATE425962T1 (de) Peptid-deformylase-hemmer
DE60332204D1 (de) System zur Überwachung von Substrat-Eigenschaften
MX2010004097A (es) Complejos de los dominios de trpc y sestd1 y metodos y usos que implican los mismos.